These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 18349433)

  • 41. Assessing the cost-effectiveness of HAART for adults with HIV in England.
    Miners AH; Sabin CA; Trueman P; Youle M; Mocroft A; Johnson M; Beck EJ
    HIV Med; 2001 Jan; 2(1):52-8. PubMed ID: 11737376
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
    Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
    Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs.
    Paltiel AD; Walensky RP; Schackman BR; Seage GR; Mercincavage LM; Weinstein MC; Freedberg KA
    Ann Intern Med; 2006 Dec; 145(11):797-806. PubMed ID: 17146064
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of adherence interventions for highly active antiretroviral therapy: a systematic review.
    Mathes T; Pieper D; Antoine SL; Eikermann M
    Int J Technol Assess Health Care; 2013 Jul; 29(3):227-33. PubMed ID: 23759359
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost Effectiveness of Potential ART Adherence Monitoring Interventions in Sub-Saharan Africa.
    Phillips AN; Cambiano V; Nakagawa F; Bansi-Matharu L; Sow PS; Ehrenkranz P; Ford D; Mugurungi O; Apollo T; Murungu J; Bangsberg DR; Revill P
    PLoS One; 2016; 11(12):e0167654. PubMed ID: 27977702
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness of population-level expansion of highly active antiretroviral treatment for HIV in British Columbia, Canada: a modelling study.
    Nosyk B; Min JE; Lima VD; Hogg RS; Montaner JS;
    Lancet HIV; 2015 Sep; 2(9):e393-400. PubMed ID: 26423553
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001.
    Beck EJ; Mandalia S; Gaudreault M; Brewer C; Zowall H; Gilmore N; Klein MB; Lalonde R; Piché A; Hankins CA
    AIDS; 2004 Dec; 18(18):2411-8. PubMed ID: 15622317
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Is increased screening and early antiretroviral treatment for HIV-1 worth the investment? An analysis of the public health and economic impact of improvement in the UK.
    Brogan AJ; Talbird SE; Davis AE; Wild L; Flanagan D
    HIV Med; 2019 Nov; 20(10):668-680. PubMed ID: 31392813
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence.
    Currie CS; Floyd K; Williams BG; Dye C
    BMC Public Health; 2005 Dec; 5():130. PubMed ID: 16343345
    [TBL] [Abstract][Full Text] [Related]  

  • 50. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
    Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
    Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study.
    Sendi PP; Bucher HC; Harr T; Craig BA; Schwietert M; Pfluger D; Gafni A; Battegay M
    AIDS; 1999 Jun; 13(9):1115-22. PubMed ID: 10397543
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain.
    Rodríguez-Arenas MA; Jarrín I; del Amo J; Iribarren JA; Moreno S; Viciana P; Peña A; Sirvent JL; Vidal F; Lacruz J; Gutierrez F; Oteo JA; Asencio R; Castilla J; Hoyos SP;
    AIDS Res Hum Retroviruses; 2006 Aug; 22(8):715-23. PubMed ID: 16910826
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness of screening for anal cancer using regular digital ano-rectal examinations in men who have sex with men living with HIV.
    Ong JJ; Fairley CK; Carroll S; Walker S; Chen M; Read T; Grulich A; Bradshaw C; Kaldor J; Clarke P
    J Int AIDS Soc; 2016; 19(1):20514. PubMed ID: 26942721
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness of an intervention to reduce HIV/STI incidence and promote condom use among female sex workers in the Mexico-US border region.
    Burgos JL; Gaebler JA; Strathdee SA; Lozada R; Staines H; Patterson TL
    PLoS One; 2010 Jun; 5(6):e11413. PubMed ID: 20617193
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens.
    Horberg M; Silverberg M; Hurley L; Delorenze G; Quesenberry C
    AIDS Patient Care STDS; 2008 Apr; 22(4):301-12. PubMed ID: 18338961
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modelling the cost-effectiveness of HIV care shows a clear benefit when transmission risk is considered in the calculations - A message for Central and Eastern Europe.
    Kowalska JD; Wójcik G; Rutkowski J; Ankiersztejn-Bartczak M; Siewaszewicz E
    PLoS One; 2017; 12(11):e0186131. PubMed ID: 29131849
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness.
    Desai K; Sansom SL; Ackers ML; Stewart SR; Hall HI; Hu DJ; Sanders R; Scotton CR; Soorapanth S; Boily MC; Garnett GP; McElroy PD
    AIDS; 2008 Sep; 22(14):1829-39. PubMed ID: 18753932
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men.
    Palefsky JM; Holly EA; Efirdc JT; Da Costa M; Jay N; Berry JM; Darragh TM
    AIDS; 2005 Sep; 19(13):1407-14. PubMed ID: 16103772
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HIV antiretroviral treatment: early versus later.
    Mauskopf J; Kitahata M; Kauf T; Richter A; Tolson J
    J Acquir Immune Defic Syndr; 2005 Aug; 39(5):562-9. PubMed ID: 16044008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.